Home/Stocks/COGT

COGT

USD

Cogent Biosciences Inc. Common Stock

$14.130-1.110 (-7.283%)

Real-time Price

Healthcare

Biotechnology

United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics

Company Fundamentals

Trading Stats

Market Metrics

Open

$15.240

High

$15.870

Low

$13.980

Volume

0.44M

Company Fundamentals

Market Cap

2.0B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

1.89M

Exchange

NMS

Currency

USD

52-Week Range

Low $3.72Current $14.130High $17.15

Related News

Nov 4, 2025 · 01:09 PM

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences with a Buy and maintains $21 price target.

Nov 3, 2025 · 02:01 PM

GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)

Nov 3, 2025 · 02:00 PM

GlobeNewswire

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;

Oct 24, 2025 · 04:30 PM

GlobeNewswire

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today